Physician profile
Julia M Nutter
NPI 1528331774
$904.29
in general payments reported to CMS, 2019-2025
18 companies · $131 in 2025
The $131 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $120 · 2022: $115 · 2023: $229 · 2024: $309 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $669.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $669.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $198.06 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $107.01 | 2022-2025 | |
| Avion Pharmaceuticals | $90.34 | 2023 | Dhivy |
| Valinor Pharma, LLC | $68.35 | 2024-2025 | Movantik |
| Takeda Pharmaceuticals U.S.A., INC. | $64.82 | 2021 | |
| Amgen INC. | $46.44 | 2022-2024 | Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $40.78 | 2023-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $38.07 | 2021-2025 | Gardasil 9, Capvaxive |
| Biohaven Pharmaceutical Holding Company Ltd. | $36.20 | 2022 | |
| Glaxosmithkline, LLC. | $34.96 | 2024 | Trelegy Ellipta |
| Novo Nordisk INC | $33.22 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Ascensia Diabetes Care US INC. | $27.75 | 2024 | |
| Abbvie INC. | $27.32 | 2023 | |
| Organon LLC | $24.36 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $19.11 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.15 | 2024 | Relistor |
| Scilex Pharmaceuticals INC. | $16.75 | 2024 | |
| Currax Pharmaceuticals LLC | $13.60 | 2024 | Onzetra Xsail, Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Nutter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.